XNCR Xencor Inc

8-K Current Report

Filed: March 4, 2026

Health Care

Pharmaceutical Preparations

Xencor Inc (XNCR) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Alexion (AstraZeneca sub) unilaterally stopped U.S. royalty payments on Ultomiris®, disputing obligation under existing license agreement
• At risk: $100–$120M in aggregate royalties Xencor expected to receive through 2028 on U.S. Ultomiris sales

+3 more insights

Other Xencor Inc 8-K Filings

8-K Mar 9, 2026

8-K Feb 25, 2026

Get deeper insights on Xencor Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.